A Phase 1/2 interventional study of human umbilical cord mesenchymal stem cells in Hereditary Ataxia, sponsored by Shenzhen Beike Bio-Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-11-28.
Sponsored by Shenzhen Beike Bio-Technology Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Spinocerebellar Degenerations with a site in China — 7 open to participants now, 7 under way, 2 of them phase 3. Spinocerebellar Degenerations · China.
Among the 10 studies in Spinocerebellar Degenerations with a site in China, this one is the only one that started in 2010, is the only one in phase 1/2, and was the 1st registered.
49 studies on the registry are indexed under Spinocerebellar Degenerations; 15 are open to participants now.
Browse Spinocerebellar Degenerations studies →7 of the 10 studies in Spinocerebellar Degenerations with a site in China are open now. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–65
Sun Yat-sen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 9 Spinocerebellar Degenerations studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 16 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 3
First in 2010; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 45 across 36 interventional studies indexed under Spinocerebellar Degenerations.
Median enrollment 140 across the 7 interventional studies, 500 across the 3 observational. Of the 1 that completed or were terminated, 1 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 8 most frequent:
Shenzhen Beike Bio-Technology Co., Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Shenzhen Beike Bio-Technology Co., Ltd. has 1 study filed under Spinocerebellar Degenerations — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Spinocerebellar Degenerations with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Hereditary Ataxias are a group of genetic disorders characterized by slowly progressive incoordination of gait and often associated with poor coordination of hands, speech, and eye movements. Current treatments for Hereditary Ataxias are mainly pharmacological, rehabilitative, or psychological treatments,while no effective treatment available. Stem Cell therapy is a novel and promising therapeutic strategy for Hereditary Ataxias treatment. In this study, the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells transplantation will be evaluated in patients with Hereditary Ataxias.
This Study is designed to evaluate the the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells transplantation in patients with Hereditary Ataxias.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be given umbilical cord mesenchymal stem cells transplantation with a 1 year follow-up.
Biological: human umbilical cord mesenchymal stem cells
Participants will be given hUC-MSCs transplantation.
Also known as: Intervention Group
scores of International Cooperative Ataxia Rating Scale (ICARS) scale and Berg Scale
Time frame: 1 year after treatment
the volume of Cerebellum of Brain Magnetic Resonance Imaging (MRI) Scan
Time frame: 1 year after treatment
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time frame: 1 year after treatment
Number of Participants with Serious Adverse Events as a Measure of Safety and Tolerability
Time frame: 1 year after treatment
The record gives a start of Jan 2010, a primary completion of Dec 2012 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solizmestrocel
Spinocerebellar Degenerations →
Shenzhen Beike Bio-Technology Co., Ltd.